Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Bijal Shah, Ryan J. Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Michael Haddadin, Nitin Jain, Brian A. Jonas, Suzanne Kirby, Michaela Liedtke, Mark R. Litzow, Aaron C. Logan, Meixiao Long, Selina M. Luger, James K. Mangan, Stephanie Massaro, William May, Olalekan O. Oluwole, Jae H. Park, Amanda Przespolewski, Sravanti Rangaraju, Caner Saygin, Marc S. Schwartz, Paul J. Shami, Benjamin Tomlinson, Jonathan Webster, Ajibola Awotiwon, Katie Stehman
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.